Abstract PD3-07: Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study
Year: 2021
Type: conference-abstract
Source: Cancer Research
Authors: Erika Hamilton, Charles L Shapiro, Daniel Petrylak, Valentina Boni, Miguel Martin, Gianluca Del Conte, Javier Cortes, Laila Agarwal, Hendrik-Tobias Arkenau, Antoinette R. Tan, Philip Debruyne, Anna Minchom, Annemie Rutten, Frances Valdes-Albini, Evan Y Yu, Bincy Augustine, Anthony D'Amelio, Daniel Barrios, Sara A. Hurvitz
Institutions: Sarah Cannon, Tennessee Oncology, Icahn School of Medicine at Mount Sinai, Yale University, Hospital General Universitario Gregorio Marañón, IRCCS Ospedale San Raffaele, Vall d'Hebron Institute of Oncology, Sarah Cannon Research Institute, Levine Cancer Institute, AZ Groeninge, Institute of Cancer Research, Royal Marsden Hospital, GZA Ziekenhuizen Campus Sint-Augustinus, University of Miami, University of Washington, Fred Hutch Cancer Center, Daiichi Sankyo (United States), University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3132591297